HRT Warning Labels Changed: What It Means for Women
The short answer: In a menopause hormone therapy warning label change that began on November 10, 2025, the FDA asked makers to remove heart disease, breast cancer and probable dementia statements from the boxed warning, and the first 6 products got new labels on February 12, 2026.
- The boxed warning for endometrial cancer stays on estrogen-alone products that act on the whole body.
- New labels add the option of starting hormone therapy for hot flashes in women under 60 or within 10 years of menopause.
- About 41 million US women were aged 45 to 64 in 2020, yet only about 2 million aged 46 to 65 received a hormone therapy prescription.
Last updated October 2026.
The menopause hormone therapy warning label change is the biggest shift in how these medicines are described in more than 20 years. On November 10, 2025, the FDA asked makers to take statements about heart disease, breast cancer and probable dementia out of the boxed warning, the label’s most prominent safety warning.
Below: what changed, what did not, and why. Our guide to perimenopause and menopause has the wider picture. This is education, not advice for your own care.
What is the menopause hormone therapy warning label change?
It is a set of edits to the prescribing information for HRT. Three risk statements are leaving the boxed warning, while some risks stay in other parts of the text, so the result is shorter and different, not empty.
| Part of the label | What the FDA asked for |
|---|---|
| Boxed warning: heart disease, breast cancer, probable dementia | Remove the language |
| Boxed warning: endometrial cancer | Keep on systemic estrogen-alone products; remove from the others |
| Advice to use the lowest dose for the shortest time | Remove from the boxed warning |
| Probable dementia warning in the rest of the label | Remove |
| Heart disease and breast cancer warnings in the rest of the label | Keep |
| Starting systemic therapy for hot flashes | Add consideration for women under 60 or within 10 years of menopause |
The table follows the FDA’s notice of requested changes.
What is a boxed warning, and why did hormone therapy get one?
A boxed warning is the FDA’s most prominent safety warning for prescription drugs, according to its consumer update. Hormone therapy got one after the Women’s Health Initiative (WHI), a large US study whose early results came out in 2002.
The 2002 trial gave 16,608 women aged 50 to 79 either estrogen plus progestin or a placebo. It was stopped after a mean of 5.2 years because breast cancer cases had crossed its safety limit. Per 10,000 women a year, the hormone group had 8 more strokes and 8 more invasive breast cancers, and 5 fewer hip fractures.
The FDA says that in 2003 it began approving class-wide label changes based on these findings. They eventually included a boxed warning for cardiovascular disorders, invasive breast cancer and probable dementia.
Why did the FDA change the warning label?
The FDA says the WHI women did not match the women who usually start hormone therapy. The average WHI participant was 63, while bothersome hot flashes typically start between 45 and 55. The dementia studies enrolled women aged 65 to 79.
Later data point the same way. A 2013 report on both WHI trials, covering 27,347 women, found the balance of risks and benefits varied by age. With estrogen plus progestin, the overall risk was 12 extra cases per 10,000 women a year at ages 50 to 59 and 38 at ages 70 to 79. With estrogen alone, it was 19 fewer cases at 50 to 59 and 51 extra at 70 to 79.
The authors added that the therapy was not supported for protecting long-term health, though it was appropriate for symptom relief in some women.
Low use is the other reason. About 41 million US women were aged 45 to 64 in 2020, and moderate to severe hot flashes were found in about 34% of women aged 45 to 65 in a 2021 study. Yet only about 2 million women aged 46 to 65 received a prescription. The FDA held an expert panel on July 17, 2025, before acting.
“Millions of women have avoided hormone replacement therapy since the early 2000s because of fears about cancer and heart disease risks.” (U.S. Food and Drug Administration)
What did not change on the label?
Some warnings remain. The agency is not asking to remove the boxed warning for endometrial cancer on systemic estrogen-alone products, and it has not asked to remove heart disease and breast cancer risks from the Warnings and Precautions section, according to its consumer update.
The “lowest dose for the shortest time” line came out of the boxed warning, but the National Institute on Aging still says that if hormone therapy is right for you, it should be at the lowest dose, for the shortest period of time it remains effective. Doctors may differ on this, so ask yours.
Which hormone therapy products have the new labels?
As of the FDA’s list, last updated February 12, 2026, six products have approved changes. They come from each of the four main types: systemic combination therapy, systemic estrogen-alone therapy, progestogen-alone therapy for women with a uterus using systemic estrogen, and topical vaginal estrogen. See the FDA’s list of updated products for names.
At the FDA’s request, 29 drug companies have submitted proposed changes. More companies may update, so a product at your pharmacy may still carry the old text for now.
Does the change mean hormone therapy is right for every woman?
No. A shorter boxed warning does not mean no risk. Other risks are still listed, and the new wording only says doctors may consider starting therapy for moderate to severe hot flashes in women under 60 or within 10 years of menopause.
Form and history matter. The NIA notes that patches may be best for women with cardiac risk factors, such as a family history of heart disease. The FDA has also approved three nonhormone options for women who cannot or choose not to use hormones; our menopause guide covers them.
What can you ask your doctor about hormone therapy?
Bring your own numbers to the visit. Useful questions, based on what the label turns on:
- How many years has it been since my last period, and how old am I now?
- Which type fits me: combination, estrogen alone, or vaginal estrogen?
- Would a patch, gel or pill suit my heart and family history better?
- How long should I plan to use it, and when will we review it?
- Are nonhormone options worth trying first?
For more on this life stage, browse our menopause coverage.
Frequently asked questions
What is a boxed warning on a medicine?
A boxed warning is the FDA’s most prominent safety warning for prescription drugs. It flags potentially serious or life-threatening risks that you and your doctor should weigh when deciding on a medicine.
Did the FDA remove every warning from hormone therapy?
No. The FDA asked for heart disease, breast cancer and probable dementia statements to come out of the boxed warning. The endometrial cancer boxed warning stays on estrogen-alone products that act on the whole body, and heart disease and breast cancer risks remain in the warnings section.
Does the new label say hormone therapy is safe for all women?
No. The label adds the option of starting hormone therapy for moderate to severe hot flashes in women under 60 or within 10 years of menopause. Whether it fits you depends on your age, health history and symptoms, which is a decision for you and your doctor.
Does the label change apply to vaginal estrogen?
Yes. The FDA asked for the boxed warning changes on all hormone therapy products, including vaginal estrogen. For vaginal products, it also asked makers to condense the safety information and focus on what matters for that form.
This article is for education and is not medical advice. Talk to your doctor before changing your diet, supplements, or medication.
Health Science Mag is an educational publication. Articles are for information only and are not medical advice. Talk to your clinician before changing your supplement routine.
